
Opinion|Videos|June 1, 2024
The Evolving Treatment Landscape in BCG-Unresponsive NMIBC
Bladder cancer experts discuss the evolving treatment landscape in BCG-unresponsive NMIBC and give an overview of TAR-200, an emerging therapy.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
2
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
3
Amy E. Krambeck, MD, on choosing between CVAC and FANS for suction-based ureteroscopy
4
Trial launches of actinium (225Ac) rhPSMA-10.1 injection in mCRPC
5














